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Abstract: In rodent skeletal muscle, acyl-coenzyme A (CoA) synthetase 5 (ACSL-5) is suggested
to localize to the mitochondria but its precise function in human skeletal muscle is unknown.
The purpose of these studies was to define the role of ACSL-5 in mitochondrial fatty acid
metabolism and the potential effects on insulin action in human skeletal muscle cells (HSKMC).
Primary myoblasts isolated from vastus lateralis (obese women (body mass index (BMI) =
34.7 ± 3.1 kg/m2)) were transfected with ACSL-5 plasmid DNA or green fluorescent protein (GFP)
vector (control), differentiated into myotubes, and harvested (7 days). HSKMC were assayed for
complete and incomplete fatty acid oxidation ([1-14C] palmitate) or permeabilized to determine
mitochondrial respiratory capacity (basal (non-ADP stimulated state 4), maximal uncoupled (carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)-linked) respiration, and free radical (superoxide)
emitting potential). Protein levels of ACSL-5 were 2-fold higher in ACSL-5 overexpressed HSKMC. Both
complete and incomplete fatty acid oxidation increased by 2-fold (p < 0.05). In permeabilized HSKMC,
ACSL-5 overexpression significantly increased basal and maximal uncoupled respiration (p < 0.05).
Unexpectedly, however, elevated ACSL-5 expression increased mitochondrial superoxide production
(+30%), which was associated with a significant reduction (p < 0.05) in insulin-stimulated p-Akt and
p-AS160 protein levels. We concluded that ACSL-5 in human skeletal muscle functions to increase
mitochondrial fatty acid oxidation, but contrary to conventional wisdom, is associated with increased
free radical production and reduced insulin signaling.
Keywords: ACSL-5; fatty acid oxidation; insulin signaling; mitochondria; ROS; skeletal muscle
1. Introduction
Growing scientific evidence suggests that a central and precipitating factor for the development of
obesity-associated skeletal muscle insulin resistance is the presence of a cellular lipid load that exceeds
mitochondrial energy demand, leading to organelle dysfunction and disruption [1–6]. In support of
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this hypothesis, several reports have indicated that mitochondrial lipid oxidation is impaired in skeletal
muscle from obese and type 2 diabetic subjects [7–11], likely due in part to reduced mitochondrial
content and/or respiratory activity [8].
Long-chain acyl-CoA synthetase (ACSL) catalyzes the ligation of coenzyme A (Co-A) to long-chain
fatty acids to form fatty acyl-CoA, which is then partitioned to either the mitochondria for oxidation
or toward the triacylglycerol synthesis pathway for storage [12,13]. In addition to declines in
mitochondrial content, skeletal muscle lipid oxidation could be reduced by impaired ACSL function
leading to the accumulation of lipid intermediates including diacylglycerols, which are thought to
activate serine/threonine kinases (e.g., inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ),
c-Jun N-terminal kinase (JNK), protein kinase C theta (PKCθ)) [14] that phosphorylate and inhibit
insulin receptor substrate 1 (IRS1), thus downregulating insulin signaling [3,6,15–17]. Total ACSL
activity has been previously noted in skeletal muscle from obese women [18,19], yet isoform-specific
function within human skeletal muscle has not been determined.
To date, five ACSL isoforms have been identified and characterized in rodents and humans [20–23].
Each of the ACSL family members is thought to have a distinct tissue distribution, intracellular
localization (e.g., endoplasmic reticulum, mitochondria, peroxisomes), and expression level in response
to metabolic challenges [12,13,22,24–28]. The majority of data on ACSL function has been obtained
in liver from rodents with far fewer studies conducted in skeletal muscle [28], and even fewer from
humans. In addition, whereas several ACSL isoforms are involved in non-oxidative functions, such as
lipid synthesis [29] and biogenesis of organelle membranes, at least one isoform, ACSL-5, is believed
to be associated with the mitochondrial outer membrane, suggesting a role for partitioning long-chain
fatty acids toward oxidation [20,22,23,30–32].
Despite the popularity of the aforementioned hypothesis linking reduced mitochondrial lipid
oxidation with disruptions in the insulin signaling cascade, more recent studies also suggest a
relationship between mitochondrial fatty acid uptake and production of free radicals. More specifically,
studies from our laboratory have recently linked lipid induced mitochondrial free radical production
with reductions in insulin sensitivity [5].
Skeletal muscle is responsible for the majority of lipid oxidation in mammals; however, the
role of ACSL-5 in regulating skeletal muscle mitochondrial fatty acid oxidation and the potential
indirect influence over mitochondrial electron transport chain function and insulin action in humans
remains unknown. Therefore, the purpose of this study was to investigate the potential role of ACSL-5
in mitochondrial function, including lipid oxidation, free radical formation, and insulin signaling.
Herein, we report the novel findings that ACSL-5 in human skeletal muscle functions to increase fatty
acid oxidation in mitochondria, in conjunction with unexpected findings of increased free radical
production and reduced insulin signaling.
2. Materials and Methods
2.1. Human Subjects and Tissue Biopsy
Six premenopausal, non-diabetic obese women participated in this study. Obese subjects (body
mass index (BMI) = 34.7 ± 3.1 kg/m2; ages 26–44) were chosen because of reported reductions
in skeletal muscle fatty acid oxidation capacity [7,10]. We specifically targeted African women (at
least second generation verified by questionnaire and interviews during subject consent) because
of compromised ACSL activity [18,19]. Prescreening by questionnaires and personal interviews
demonstrated that subjects were: (1) sedentary (less than 30 min of physical activity per week for
>6 months), (2) non-smokers, and (3) had no history of metabolic disease (no subjects were taking
medications known to alter metabolism such as a thyroid hormone replacement). Skeletal muscle
biopsies were obtained from the lateral aspect of the vastus lateralis using a modification of the
percutaneous needle biopsy technique as previously reported [33]. Experiments were approved by the
Institutional Review Board of East Carolina University.
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2.2. Blood Sampling and Determination of Insulin Sensitivity
Subjects reported to the laboratory in the fasted (10 h) state. A catheter was placed in the
antecubital vein and the subjects rested for 30 min prior to blood sampling. Plasma was collected in ice
cold ethylenediaminetetraacetic acid (EDTA) treated tubes. Plasma from fasted subjects was analyzed
for glucose (YSI 2300 STAT Plus Glucose and Lactate Analyzer, YSI Inc; Yellow Springs, OH, USA) and
insulin (Access Immunoassay System, Beckman-Coulter; Fullerton, CA, USA). A homeostasis model
assessment value for insulin resistance (HOMA-IR) was calculated (HOMA-IR = (glucose, mg·dL−1 ×
insulin, µU·mL−1)/405). Insulin sensitivity was defined according to Stern et al. [34]: insulin sensitive,
HOMA-IR < 3.60; insulin resistant, HOMA-IR > 3.60.
2.3. Cell Culture and Transfection
As described previously [35], skeletal muscle fibers (60–80 mg) were transferred to chilled
Dulbecco’s Modified Eagles Medium (DMEM), and all visible fat and connective tissue were removed
before cell culture. Cells were suspended in growth media containing DMEM supplemented with
10% fetal bovine serum (FBS), 0.5 mg/mL bovine serum albumin (BSA), 0.5 mg/mL fetuin, 20 ng/mL
human epidermal growth factor, 0.39 µg/mL dexamethasone, and 50 µg/ml gentamicin/amphotericin
B, and cultured at 37 ◦C in a humidified 5% CO2 and ambient air incubator. After reaching
70–80% confluence, myoblasts were harvested via trypsinization and then counted to determine
cell density. The myoblasts (106 cells) were resuspended in 100 µL Nucleofector solution (Lonza,
Walkersville, MD, USA) combined with 3 µg ACSL-5 plasmid DNA (Invitrogen: Carlsbad, CA,
USA) and 2 µg pmaxGFP (green fluorescent protein) vector (Lonza: Walkersville, MD, USA) for the
experimental group, or only 2 µg pmaxGFP vector without ACSL-5 plasmid DNA for the control group.
The control cells were obtained from the same subjects as the experimental group. The cells/DNA
suspension was transfected using Amaxa’s Nucleofector Technology (Lonza: Walkersville, MD, USA)
according to the manufacturer’s protocol. After transfection, the myoblasts were transferred to
pre-equilibrated growth media plates for 48 h to reach 80% confluence. Growth media was switched to
differentiation media containing 2% horse-serum, 0.5 mg/mL BSA, 0.5 mg/mL fetuin, and 50 µg/mL
gentamicin/amphotericin B for the differentiation of myoblasts into myotubes. The transfection
efficiency of green fluorescent protein (GFP) and the cell viability were measured by inverted
fluorescence microscopy. Primary human myotubes were harvested and assayed on day 7 of
differentiation for all cellular experiments as previously reported by our group [35]. Verification
of transfection efficiency was confirmed via Western blot analysis using an ACSL-5 antibody (1:1000,
Santa Cruz Biotechnology: Santa Cruz, CA, USA).
2.4. Measurement of Fatty Acid Oxidation
Experiments utilizing [1-14C] palmitate was performed to measure fatty acid oxidation in
the primary human skeletal myotubes according to modified methods of Cortright et al. [19].
Measurements for fatty acid oxidation in primary human myotubes have been previously validated by
our group [36]. In brief, differentiated human skeletal muscle cells with or without ACSL-5 transfection
were incubated in sealed reaction plates at 37 ◦C in a humidified 5% CO2 and ambient air incubator
for 3 h. Palmitate oxidation was performed in differentiation media containing 100 µM palmitate,
12.5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.25% BSA, 1mM carnitine,
5 mM glucose, and 10 µCi/mL [1-14C] palmitate (Sigma-Aldrich, St. Louis, MO, USA). Following
the incubation period, the reactions were terminated via the addition of 50 µL 70% perchloric acid.
The incubation plate was transferred to an orbital shaker, and 14CO2 was trapped in the adjoining well
(200 µL of 1 N NaOH) for 1 h. Radioactivity as 14CO2 (complete palmitate oxidation) and 14C-ASM
(acid soluble metabolites; incomplete palmitate oxidation) was determined via liquid scintillation
counting using 4 mL of Uniscint BD (National Diagnostics, Atlanta, GA). The remaining cell pellets
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were washed twice with ice-cold phosphate-buffered saline, harvested in 200 µL 0.05% sodium dodecyl
sulfate (SDS), and stored at −80 ◦C for subsequent protein determination.
2.5. Preparation of Permeabilized Cells
After harvesting differentiated myotubes and cell counting, samples were centrifuged at 1000 rpm
for 5 min and treated with 3 µg/106 cells/mL digitonin—a mild, cholesterol-specific detergent—at
37 ◦C for 5 min with rotation. Digitonin selectively permeabilizes the sarcolemmal membranes while
keeping mitochondrial membranes intact. Following permeabilization, cells were washed using
centrifugation at 1000 rpm for 5 min to remove endogenous substrates. Permeabilized cells were used
for mitochondrial O2 respiration as previously described [35].
2.6. Measurement of Mitochondrial O2 Respiration
As described previously by our group [35], high resolution oxygen (O2) consumption
measurements were conducted at 37 ◦C using the Oroboros O2K Oxygraph (Innsbruck, Austria)
in MiR05 respiration buffer containing 130 mM sucrose, 60 mM C6H11O7K, 1mM ethylene
glycerol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 3 mM MgCl2, 10 mm K2HPO4,
20 mM HEPES, and 1 mg/mL BSA (pH 7.4). After permeabilization, cells (1.0 × 106 cells per
chamber) were placed into separate chambers with 2 mL of MiR05. Mitochondrial O2 consumption
was measured as follows: (i) 2 mM ADP/0.5 mM ATP (state 3 respiration following addition of
substrate), (ii) 100 µM palmitate + 0.1 mM CoA + 1mM carnitine (fatty acid substrates), (iii) 100
µM malonyl-CoA (CPT-1 inhibitor), (iv) 2 mM glutamate + 1mM malate (complex I substrates), (v)
3 mM succinate (complex II substrate), (vi) 10 µg/ml oligomycin (inhibitor of mitochondrial ATP
synthase, state 4 respiration), and (vii) 2 µM carbonylcyanide-p-trifluoromethoxyphenylhydrazone
(FCCP, a protonophoric uncoupler; indicator of maximal respiratory capacity). Mitochondrial integrity
was confirmed by addition of cytochrome C, while absence of endogenous substrates was confirmed
by no increase in O2 consumption with the addition of ADP prior to substrate additions.
2.7. Measurement of Mitochondrial O2− production
Mitochondrial superoxide (O2−) was measured with flow cytometry (FACS-calibur; BD Bioscience,
San Jose, CA, USA) in both control (only GFP transfected) and experimental cells (ACSL-5/GFP
plasmid DNA transfected) after staining with mitochondrial superoxide specific dye MitoSOX Red
(Molecular Probes, Eugene, OR, USA) as previously reported [37]. Briefly, on day 7 of differentiation
(post transfection), 5 µM MitoSOX was applied for 15 min at 37 ◦C in a CO2 incubator protected from
light followed by washing two times with Hank’s Buffered Salt Solution (HBSS). After trypsinization
and neutralization with FBS, cells were counted and centrifuged at 1000 rpm for 10 min and
resuspended with FACS buffer (PBS containing 1% BSA, 0.01% NaN3). For the positive control,
the cells were treated with 50 µM Antimycin A for 60 min. MitoSOX Red was excited using laser
exposure at 488 nm and the data were collected using FSC (forward scatter), SSC (side scatter), FL2
(588/42 nm), and FL3 (670LP) channels. In this study, the data were presented from the FL2 channel.
Quantifications were performed from the mean intensity of MitoSOX fluorescence from triplicates.
2.8. Western Immunoblot Analysis for Insulin Signaling
Protein levels for phospho-/total IRS-1, phospho-/total Akt, phospho-/total AS160, and MnSOD
were determined in the cytoplasmic protein fraction via Western immunoblot analysis. On day 7 of
differentiation, the myotubes were treated with 100 nM porcine insulin (Sigma-Aldrich, St. Louis,
MO, USA) for 10 min and then harvested in lysis buffer containing 50 mM HEPES, 10mM EDTA,
100 mM NaF, 50 mM Na pyrophosphate, 10 mM Na orthovanadate, and 1% Triton X-100 supplemented
with phosphatase and protease inhibitor cocktails (Sigma-Aldrich, St. Louis, MO, USA). The protein
concentration was determined using a BCA assay kit (Pierce Biotechnology, Rockford, IL, USA). Forty
micrograms of protein from myotube homogenates in sample buffer (+5% β-mercaptoethanol) were
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then loaded into the wells of 12.5 % polyacrylamide gels, and electrophoresed at 150 V. Proteins were
then transferred at 100 V for 2 h onto a polyvinylidene fluoride (PVDF) membrane. After staining with
Ponceau S (Sigma-Aldrich, St. Louis, MO, USA) to verify equal loading, the membranes were blocked
in 5% nonfat milk in tris-buffered saline (TBS) with 0.1% Tween-20 for 4 h. After blocking, membranes
were incubated at 4 ◦C in blocking buffer for 12 h with the appropriate primary antibodies: rabbit
polyclonal anti-phospho-IRS-1 (1:1000, Upstate: Lake Placid, NY, USA), rabbit polyclonal anti-IRS-1
(1:1000, Upstate: Lake Placid, NY, USA), rabbit polyclonal anti-phospho-Akt1/2/3 (Ser 473) (1:500,
Santa Cruz Biotechnology: Santa Cruz, CA, USA), rabbit polyclonal anti-Akt1/2/3 (H-136) (1:500,
Santa Cruz Biotechnology: Santa Cruz, CA, USA), rabbit polyclonal anti-phospho-AS160 (T642) (1:1000,
Invitrogen: Carlsbad, CA, USA), and rabbit polyclonal anti-AS160 (1:4000, Upstate: Lake Placid, NY,
USA), and rabbit polyclonal anti-MnSOD (1:10,000, Stressgen: Ann Arbor, MI, USA). Following three
washings in TBS with 0.1% Tween-20, membranes were incubated at room temperature for 60 min
in blocking buffer with horseradish peroxidase (HRP)–conjugated secondary antibodies (Santa Cruz
Biotechnology). An enhanced chemiluminescence (ECL) detection system (Amersham: Piscataway,
NJ, USA) was used for visualization. The membranes were stripped and re-probed with a GAPDH
antibody (1:4000, Advanced Immunochemical: Long Beach, CA, USA) to verify equal loading among
lanes as an internal control. Densitometry (as area times grayscale relative to background) was
performed using a Kodak film cartridge and film, a scanner interfaced with a microcomputer, and the
NIH Image Analysis 1.62 software program (National Institutes of Health, Bethesda, MD, USA).
2.9. Morphological Imaging
Morphological changes and survival of transfected cells were monitored by obtaining
photomicrographs under an inverted phase contrast microscopy (Olympus America Inc.: Melville, NY,
USA) with a digital camera.
2.10. Statistics
All experiments were conducted in parallel with experimental and control cells from the same
subjects. For all data analysis except group comparisons for insulin signaling, a Student’s paired
t-test was employed to determine the existence of mean differences between the ACSL-5 transfected
experimental group and control group. For insulin signaling data, group means were compared
using a one way ANOVA. Data were presented means ± standard error mean (SEM), with statistical
significance between groups established a priori at p < 0.05.
3. Results
3.1. Human Subjects
Table 1 presents the characteristics for the subjects. The mean value for BMI was approximately
35 kg/m2, thus indicating that they were not morbidly obese. Participants were not considered insulin
resistant as determined using HOMA-IR (2.8 ± 0.4).
Table 1. Subject characteristics.
Variables Obese Subjects
Numbers 6
Age (years) 33.0 ± 2.7
Height (cm) 167.2 ± 2.1
Weight (kg) 97.3 ± 8.3
BMI (kg/m2) 34.7 ± 3.1
% fat 44.9 ± 2.5
HOMA-IR 2.8 ± 0.4
Data from women recruited for skeletal muscle biopsies. Abbreviations: BMI, body mass index; HOMA-IR,
homeostasis model assessment for insulin resistance.
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3.2. GFP Fluorescence and ACSL-5 Overexpression via Transfection
To determine transfection efficiency using the Amaxa Nucleofector device, primary human
skeletal myoblasts were transfected via positive control vector GFP plasmid DNA. Cell viability
was approximately 40% and transfection efficiency was approximately 50% at 24 h after transfection
in myoblasts (Figure 1A). Seven days of differentiation demonstrated a strong expression of GFP
fluorescence with fully differentiated cells being elongated and multinucleated (Figure 1B). These data
indicate successful transfection using GFP plasmid DNA in differentiated primary human skeletal
muscle cells.
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3.3. ACSL-5 Overexpression Increased Complete and Incomplete Fatty Acid Oxidation
To determine the effects of ACSL-5 overexpression on fatty acid oxidation in primary human
skeletal myotubes, we measured radioactivity of CO2 (complete fatty acid oxidation) and ASM
(incomplete fatty acid oxidation) using liquid scintillation counting. According to captured
1-14C-labeled CO2, oxidation of palmitate prepared from human skeletal myotubes was significantly
elevated (+112%; p < 0.05) in ACSL-5 overexpressing cells versus control (Figure 2A).
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approximately 2-fold higher in the ACSL-5 transfected group compared with the GFP-only transfected
control (A). Similarly, palmitate incomplete oxidation (ASM production) was significantly increased
by ACSL-5 overexpression (B). Data are expressed as presented as mean ± SEM (n = 6). * p < 0.05
versus control.
In addition, ACSL-5 overexpression resulted in a significant increase (+71%; p < 0.05) in incomplete
(14C-labeled ASM radioactivity) palmitate oxidation when compared with the control (Figure 2B).
Our findings are consistent with the hypothesis that ACSL-5 overexpression leads to an increase of
fatty acid oxidation in primary human skeletal myotubes.
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oligomycin (inhibitor of mitochondrial ATP synthase, non-ADP stimulated basal state 4), and (vii) 2 
μM carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP, a protonophoric uncoupler, 
maximal uncoupled respiration) (open bar, control cells; closed bar, ACSL-5 transfected cells). The 
rate of O2 consumption was expressed as pmol/sec/million cells. Data are presented as mean ± SEM 
(n = 6). * p < 0.05 versus control (CON). 
Protein levels of p-IRS-1 (Ser307), total IRS-1 or p- to total IRS-1 ratio were not altered by ACSL-
5 overexpression in human skeletal myotubes compared with non-ACSL-5 transfected control 
(Figure 4A). In addition, there were no effects of insulin treatment on protein levels in either control 
cells or ACSL-5 overexpressing cells (Figure 4A). However, the protein levels of p-Akt (Ser473) and 
p- to total Akt ratio in human skeletal myotubes were significantly lower (p < 0.05) compared with 
insulin-stimulated control cells (total Akt protein levels not affected) (Figure 4B). Moreover, insulin 
treatment resulted in a significant increase (p < 0.05) in protein levels of p-Akt only in control cells 
(Figure 4B). AS160, the downstream target of Akt that inhibits GLUT-4 translocation to the cell 
surface via inactivation of Rab GTPase-activating protein (GAP), expressed a pattern similar to Akt 
with ACSL-5 overexpression (Figure 4C). The protein levels of p-AS160 (T642) and p- to total AS160 
ratio were decreased (p < 0.05) by ACSL-5 overexpression in primary human skeletal myotubes 
compared with control without affecting total AS160 protein levels (Figure 4C). 
3.6. ACSL-5 Overexpression Increased Mitochondrial Oxidative Stress  
Oxidation of fatty acids is associated with elevated mitochondrial reactive oxygen species (ROS) 
production [38]. Mitochondrial ROS production has been linked to the development of insulin 
resistance in skeletal muscle [5]. To examine if ACSL-5 overexpression influences mitochondrial ROS 
production, mitochondrial superoxide production and manganese superoxide dismutase (MnSOD 
catalyzes dismutation of superoxide to H2O2) expression were determined in differentiated human 
skeletal muscle cells. Mean fluorescence intensity of oxidized MitoSOX Red determined using FACS 
analysis was increased (p < 0.05) by 30 % in primary human skeletal myotubes overexpressing ACSL-
5 (Figure 5A–D). 
Figure 3. Effect of ACSL-5 overexpression on mitochondrial oxygen consumption measured in
permeabilized primary human skeletal myotubes. The following multiple substrate protocols were
commenced for mitochondrial O2 consumption: (i) 2 mM ADP/0.5 mM ATP (state 3 following
addition of substrates), (ii) 0.1 mM palmitate + 0.1 mM CoA + 1 mM carnitine (fatty acid substrates,
state 3), (iii) 0.1 mM malonyl-CoA (CPT-1 inhibitor, state 3), (iv) 2 mM glutamate + 1 mM malate
(complex I substrates, state 3), (v) 3 mM succinate (complex II substrate, state 3), (vi) 10 µg/mL
oligomycin (inhibitor of mitochondrial ATP synthase, non-ADP stimulated basal state 4), and (vii) 2
µM carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP, a protonophoric uncoupler, maximal
uncoupled respiration) (open bar, control cells; closed bar, ACSL-5 transfected cells). The rate of O2
consumption was expressed as pmol/sec/million cells. Data are presented as mean ± SEM (n = 6).
* p < 0.05 versus control (CON).
3.5. ACSL-5 Overexpression Reduces Insulin Siganling
Elevations in fatty acyl-CoA are associated with lipid storage and insulin resistance through
increased diacylglycerides, serine kinases, or ceramide production in skeletal muscle [16]. In order to
determine whether ACSL-5 overexpression results in alterations in insulin signaling, we measured the
protein levels of IRS-1, Akt, and AS160 in differentiated primary human skeletal myotubes.
Protein levels of p-IRS-1 (Ser307), total IRS-1 or p- to total IRS-1 ratio were not altered by
ACSL-5 overexpression in human skeletal myotubes compared with non-ACSL-5 transfected control
(Figure 4A). In addition, there were no effects of insulin treatment on protein levels in either control
cells or ACSL-5 overexpressing cells (Figure 4A). However, the protein levels of p-Akt (Ser473) and
p- to total Akt ratio in human skeletal myotubes were significantly lower (p < 0.05) compared with
insulin-stimulated control cells (total Akt protein levels not affected) (Figure 4B). Moreover, insulin
treatment resulted in a significant increase (p < 0.05) in protein levels of p-Akt only in control cells
(Figure 4B). AS160, the downstream target of Akt that inhibits GLUT-4 translocation to the cell surface
via inactivation of Rab GTPase-activating protein (GAP), expressed a pattern similar to Akt with
ACSL-5 overexpression (Figure 4C). The protein levels of p-AS160 (T642) and p- to total AS160 ratio
were decreased (p < 0.05) by ACSL-5 overexpression in primary human skeletal myotubes compared
with control without affecting total AS160 protein levels (Figure 4C).
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into the mitochondria. Our findings are consistent with previous studies in other tissues. For example, 
Zhou et al. [30] reported that overexpression of ACSL-5 in liver resulted in fatty acid partitioning 
toward β-oxidation. 
Overexpression of ACSL-5 also increased the ASM production of palmitate (metabolites from β-
oxidation and the TCA cycle) (Fig. 2B). This is clinically important for cellular bioenergetics as Koves 
et al. [39] reported that insulin resistance was associated with increased incomplete fatty acid 
oxidation in skeletal muscle and argued for a connection between the development of insulin 
resistance and lipid-induced mitochondrial overload by incomplete fatty acid oxidation. The authors 
put forth the hypothesis that insulin resistance might result from excessive rather than reduced β-
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Figure 4. Effect of ACSL-5 overexpression on insulin signaling. Protein levels of phospho-/total
IRS-1 (A), phospho-/total Akt (B), and phospho-/total AS160 (C) were measured using Western
immunoblot analysis (open bar, control cells; closed bar, ACSL-5 transfected cells). Western blots and
mean (±SEM) data (n = 6) in the absence or presence of insulin treatment were presented. a p < 0.05
versus non-insulin-treated control; b p < 0.05 versus insulin-treated control (CON).
3.6. ACSL-5 Overexpression Increased Mitochondrial Oxidative Stress
Oxidation of fatty acids is associated with elevated mitochondrial reactive oxygen species (ROS)
production [38]. Mitochondrial ROS production has been linked to the development of insulin
resistance in skeletal muscle [5]. To examine if ACSL-5 overexpression influences mitochondrial ROS
production, mitochondrial superoxide production and manganese superoxide dismutase (MnSOD
catalyzes dismutation of superoxide to H2O2) expression were determined in differentiated human
skeletal muscle cells. Mean fluorescence intensity of oxidized MitoSOX Red determined using FACS
analysis was increased (p < 0.05) by 30 % in primary human skeletal myotubes overexpressing ACSL-5
(Figure 5A–D).
Moreover, MnSOD protein was significantly higher (+119%; p < 0.05) in ACSL-5 overexpressing
compared with control cells (Figure 5E), suggesting an adaptive response to elevated ROS by ACSL-5
overexpression. These findings demonstrate that ACSL-5 overexpression increased skeletal muscle
mitochondrial ROS generation and that this may be associated with alterations of certain aspects of the
insulin signaling cascade.
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Figure 5. Effects of ACSL-5 overexpression on mitochondrial superoxide production (A–D) and
MnSOD protein levels (E). Representative histograms of flow cytometry experiments were presented
demonstrating mean fluorescence intensity (GFP-control: 38.1, ACSL-5 + GFP overexpression treatment:
50.1) of oxidized MitoSOX Red mitochondrial superoxide (O2−) indicator from control group (only
GFP transfected cells) (A), ACSL-5 + GFP transfected group (B), and overlay with control and ACSL-5
overexpressed group (C). Relative superoxide production was significantly increased in ACSL-5
overexpressed group compared with the control (D). Data are presented as mean ± SEM (n = 5). * p <
0.05 versus control. The protein levels of MnSOD (anti-oxidant enzyme) were dramatically increased by
ACSL-5 overexpression (open bar, control cells; closed bar, ACSL-5 transfected cells) (E). Western blots
and mean (±SEM) data (n = 6) normalized to GAPDH in the absence or presence of insulin treatment
were presented. a p < 0.05 versus non-insulin-treated control; b p < 0.05 versus insulin-treated control
(CON).
4. Discussion
To our knowledge, this is the first report to demonstrate that elevated ACSL-5 expression in
human skeletal muscle functions to increase mitochondrial fatty acid oxidation. However, contrary to
conventional wisdom’s prediction that elevating mitochondrial fatty acid oxidation would attenuate
the progression toward insulin resistance in skeletal muscle [3], ACSL-5 was also associated with
increased free radical production (i.e., O2− ) and reduced insulin signaling.
The present data demonstrate that ACSL-5 overexpression resulted in increased complete fatty
acid oxidation (Figure 2A) and mitochondrial respiration in the absence of an inhibitory effect of
malonyl-CoA (Figure 3), suggesting that ACSL-5 overexpression induced increases in fatty acid flux
into the mitochondria. Our findings are consistent with previous studies in other tissues. For example,
Zhou et al. [30] reported that overexpression of ACSL-5 in liver resulted in fatty acid partitioning
toward β-oxidation.
Overexpression of ACSL-5 also increased the ASM production of palmitate (metabolites from
β-oxidation and the TCA cycle) (Figure 2B). This is clinically important for cellular bioenergetics as
Koves et al. [39] reported that insulin resistance was associated with increased incomplete fatty acid
oxidation in skeletal muscle and argued for a connection between the development of insulin resistance
and lipid-induced mitochondrial overload by incomplete fatty acid oxidation. The authors put forth
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the hypothesis that insulin resistance might result from excessive rather than reduced β-oxidation in
skeletal muscle.
To extend the hypothesis by Koves et al. [39], we suggest that increased lipid supply to the
mitochondria following ACSL-5 overexpression could lead to elevated NADH and FADH2 from
β-oxidation, indicative of an imbalance between substrate availability and energetic demands.
If β-oxidation is increased by oversupply of fatty acids without a corresponding increase in energy
demand, as likely occurs in the obese human, surplus reducing equivalents are generated, which
would result in an increased mitochondrial membrane potential, leading to increased mitochondrial
oxidative stress [40,41]. This elevation in mitochondrial reactive oxygen species (ROS) generation could
result in impaired insulin signaling in skeletal muscle [42,43]. Support for this contention can be found
in the recent report by our group, which provides convincing evidence of a direct cause-and-effect
relationship between increased mitochondrial lipid influx, excess ROS production, and attenuation
of glucose uptake/insulin sensitivity [5]. Thus, we recently demonstrated that administration of a
mitochondrial targeted antioxidant (SS31) and elevated mitochondrial-targeted catalase prevented
high fat diet-induced insulin resistance [5], suggesting that mitochondrial ROS may be a critical
factor in the etiology of insulin resistance in skeletal muscle. The current findings are consistent with
this hypothesis as we found that mitochondrial superoxide (O2•−) was significantly increased by
ACSL-5 overexpression in differentiated primary human skeletal muscle cells (Figure 5A–D). Moreover,
MnSOD protein levels were dramatically increased (Figure 5E). One explanation for these observations
is that the elevation in MnSOD represents a provoked cellular defense response to buffer elevating
mitochondrial superoxide content/production during conditions of cellular lipid overload, but that
this compensation was insufficient to completely curtail a rise in total ROS production. Together,
ACSL-5 overexpression may induce insulin resistance through a mechanism of increased mitochondrial
ROS production in skeletal muscle.
Given the above observations, we elected to examine the potential effects of ACSL-5
overexpression on the insulin signaling cascade. Overexpression led to an impairment of the insulin
signaling cascade by reducing the phosphorylation of Akt and downstream AS160 in the absence of
changes in upstream IRS-1 serine phosphorylation (Figure 4). In the obese population, there may be
a hyper-serine phosphorylation of IRS-1 that masked any effects of ACSL-5 overexpression at that
phosphorylation event, yet might trigger downstream signaling. Moreover, IRS-1 phosphorylation by
serine/threonine kinases (e.g., IKKβ, JNK, PKCθ) may be associated with its impaired phosphorylation
by tyrosine residues. Therefore, future directions could examine other phosphorylation events
such as tyrosine. In this context, many studies linking obesity with reductions in insulin signaling
have indicated that diminished mitochondrial function/content is the initial homeostatic alteration
associated with the development of insulin resistance in skeletal muscle [6,11,44–48]. Thus, earlier
attention had focused on accumulation of lipid intermediates such as acyl-CoA, diacylglycerol or
ceramides that inhibit insulin signaling in skeletal muscle [3,6,15–17]. These findings provide support
for the hypothesis that diminished fatty acid import and oxidation in mitochondria result in increased
lipid intermediates, such as acyl-CoA, that are the provocateurs of reduced insulin signaling and
insulin resistance. Our findings do not support these earlier observations entirely as an increased
mitochondrial fatty acid oxidation or increased basal and maximal respiration (FCCP) were not
associated with an improvement, but rather a decline in insulin signaling. Interestingly, we had earlier
demonstrated that long-chain fatty acyl-CoA accumulation in skeletal muscle is not due solely to a
reduction in fatty acid oxidation [10], nor is obesity itself always associated with reduced mitochondrial
oxidation of fatty acids [49–51]. Thus, other reports and the present study suggest at least a partial
disconnection between reduced mitochondrial oxidation of fatty acids and reductions in skeletal
muscle insulin signaling and resultant insulin resistance reported with obesity [52].
A limitation of the current study may be the investigation of ACSL-5 overexpression in skeletal
muscle cells solely from obese African-American women. However, we chose this approach
intentionally because obese African-American women are reported to demonstrate attenuation of
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ACSL activity in skeletal muscle [18,19] and because of our reports of reduced fatty acid oxidation
capacity in obese subjects [7,10]. Thus, it was not the intent of the current studies to make comparisons
among racial groups, between males and females, nor to compare lean versus obese subjects. Although
such comparisons are warranted in future studies, we conjectured in the current study that ACSL-5
overexpression would restore the reduced oxidative capacity of obese African-American women and
accordingly found that ACSL-5 overexpression increased fatty acid oxidation in human skeletal muscle.
However, the results also show that enhanced ACSL-5-dependent fatty acid oxidation occurred under
conditions of concomitant increases in mitochondrial oxidative stress. The hypothesis has been put
forth that inductions of fatty acid oxidation would serve to increase the supply of reducing molecules
(i.e., NADH and FADH2), which would increase electron “slippage” from the electron transfer chain
(ETC) and increase superoxide production and H2O2 production [5]. In addition, this study only
focused on the effects of ACSL-5 overexpression on fatty acid oxidation, ROS, and insulin signaling in
human skeletal muscle. However, it is warranted in future studies to examine the effects of ACSL-5
gene knockdown as well.
A second limitation to the current study may lie with the experimental condition to test the
potential changes in ACSL-5 expression on lipid metabolism in cell culture. Although the approach
has been acceptable in the published literature from our and other laboratories, we acknowledge the
potential limitation of the model when predicting influences of ACSL-5 in vivo with respect to PO2
levels in vitro versus in vivo cellular conditions (e.g., the current study utilized oxygen tensions of
20% vs. ≈4% in vivo). To this end, future studies in transgenic animal models overexpressing ACSL-5
are needed.
Finally, a potential limitation for the current study may lie with superoxide measurements using
mitoSOX. Given that there is an increase in MnSOD content with ACSL-5 overexpression, it may be
that the mitoSOX probe can out-compete the binding of MnSOD to superoxide. Thus, measurement
of superoxide may be underestimated. Further studies are needed to confirm the understanding of
ACSL-5 overexpression on ROS production. As such, further studies using high resolution oximetry
and measurements of H2O2 production are warranted as published earlier by our laboratory [53].
5. Conclusions
In conclusion, this is the first report of a specific ACSL isoform (ACSL-5) influencing the
mitochondrial oxidation of fatty acids in human skeletal muscle. Given contrasting findings from
previous reports in hepatocytes, it is likely that this isoform can function in a diverse manner depending
on tissue type. ACSL-5 overexpression resulted in increased complete fatty acid oxidation and
basal/maximal uncoupled respiration in differentiated primary human skeletal muscle cells. However,
ACSL-5 overexpression was also associated with increases in incomplete fatty acid oxidation and
mitochondrial oxidative stress (e.g., elevations in O2−) which might, by mechanism(s) yet to be
discovered, result in impairment of insulin signaling suggesting a coupling between cellular lipid
supply and energy demand, shifts in mitochondrial membrane potential, cellular REDOX state,
and insulin resistance in human skeletal muscle. These findings also demonstrate that in human
skeletal muscle, ACSL-5 is a contributor to mitochondrial lipid partitioning, thereby extending past
observations in rodent skeletal muscle suggesting that ACSL-1 and perhaps FATP-1 are involved in
the mitochondrial partitioning of lipids [28,54].
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